ArticleFrontiers in endocrinology2026
Refracture or death after osteoporotic fracture: five-year competing-risk and multistate trajectories.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secondary fracture prevention is a priority after osteoporotic fracture, but patients remain at substantial risk of both refracture and death. Because death precludes a subsequently observed refracture, treating it as non-informative censoring can overestimate absolute refracture risk. We therefore used competing-risk and multistate methods to characterize the 5-year trajectories of first recorded hospitalized refracture and death after osteoporotic fracture. Methods: We conducted a retrospective secondary analysis of a de-identified public longitudinal dataset comprising 4,782 patients aged ≥50 years who were hospitalized for osteoporotic fracture between 2017 and 2024. Follow-up began at discharge from the index hospitalization, and the primary analysis included patients with a survival time of ≥30 days after discharge. First recorded hospitalized refracture was the target event, and death before refracture was treated as a competing event. Cumulative incidence functions, cause-specific Cox regression, Fine-Gray regression, and Aalen-Johansen estimation were used to quantify event occurrence, assess covariate associations, and estimate four-state occupation probabilities. Results: Thirty-one patients died within 0-26 days after discharge and were excluded, leaving 4,751 patients in the primary cohort. Among these patients, 258 experienced first recorded hospitalized refracture as the first event, 487 died before recorded refracture, and 4,006 were censored before either event. At 5 years, the cumulative incidence was 8.63% (95% CI, 7.51-9.75%) for recorded hospitalized refracture and 15.57% (95% CI, 14.12-17.03%) for competing death. The corresponding Aalen-Johansen state probabilities were 75.80% for being alive without recorded refracture, 6.76% for being alive after recorded refracture, 15.57% for death without recorded refracture, and 1.88% for death after recorded refracture. Forty-seven patients had an observed refracture-to-death transition within 5 years, and the small event count limited the precision of estimates for this state. Conclusion: Among patients with a survival time of ≥30 days after discharge following osteoporotic fracture, the 5-year risk of death before recorded refracture exceeded that of first recorded hospitalized refracture. Competing-risk and multistate methods provided complementary estimates of absolute event risks and subsequent clinical trajectories. These findings are conditional on early post-discharge survival and hospitalization-based outcome capture, which may underestimate the overall refracture burden, particularly for vertebral fractures managed outside hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.